Literature DB >> 21912427

Cardiovascular diseases: Lipid-lowering in CKD--at the SHARP end of the evidence?

Suetonia C Palmer, Giovanni F M Strippoli.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21912427     DOI： 10.1038/nrneph.2011.136

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

Review 1.  Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.

Authors:  Giovanni F M Strippoli; Sankar D Navaneethan; David W Johnson; Vlado Perkovic; Fabio Pellegrini; Antonio Nicolucci; Jonathan C Craig
Journal:  BMJ       Date:  2008-02-25

2.  Sunset for statins after AURORA?

Authors:  Giovanni F M Strippoli; Jonathan C Craig
Journal:  N Engl J Med       Date:  2009-03-30       Impact factor: 91.245

3.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

4.  Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.

Authors:  Paul M Ridker; Jean MacFadyen; Michael Cressman; Robert J Glynn
Journal:  J Am Coll Cardiol       Date:  2010-03-04       Impact factor: 24.094

5.  Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.

Authors:  Michel Chonchol; Thomas Cook; John Kjekshus; Terje R Pedersen; JoAnn Lindenfeld
Journal:  Am J Kidney Dis       Date:  2007-03       Impact factor: 8.860

6.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

7.  Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  Jessica Kendrick; Michael G Shlipak; Giovanni Targher; Thomas Cook; Joann Lindenfeld; Michel Chonchol
Journal:  Am J Kidney Dis       Date:  2009-11-22       Impact factor: 8.860

Review 8.  Effect of pravastatin on cardiovascular events in people with chronic kidney disease.

Authors:  Marcello Tonelli; Chris Isles; Gary C Curhan; Andrew Tonkin; Marc A Pfeffer; James Shepherd; Frank M Sacks; Curt Furberg; Stuart M Cobbe; John Simes; Timothy Craven; Malcolm West
Journal:  Circulation       Date:  2004-09-13       Impact factor: 29.690

9.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Authors:  Bengt C Fellström; Alan G Jardine; Roland E Schmieder; Hallvard Holdaas; Kym Bannister; Jaap Beutler; Dong-Wan Chae; Alejandro Chevaile; Stuart M Cobbe; Carola Grönhagen-Riska; José J De Lima; Robert Lins; Gert Mayer; Alan W McMahon; Hans-Henrik Parving; Giuseppe Remuzzi; Ola Samuelsson; Sandor Sonkodi; D Sci; Gultekin Süleymanlar; Dimitrios Tsakiris; Vladimir Tesar; Vasil Todorov; Andrzej Wiecek; Rudolf P Wüthrich; Mattis Gottlow; Eva Johnsson; Faiez Zannad
Journal:  N Engl J Med       Date:  2009-03-30       Impact factor: 91.245

10.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Authors:  Colin Baigent; Martin J Landray; Christina Reith; Jonathan Emberson; David C Wheeler; Charles Tomson; Christoph Wanner; Vera Krane; Alan Cass; Jonathan Craig; Bruce Neal; Lixin Jiang; Lai Seong Hooi; Adeera Levin; Lawrence Agodoa; Mike Gaziano; Bertram Kasiske; Robert Walker; Ziad A Massy; Bo Feldt-Rasmussen; Udom Krairittichai; Vuddidhej Ophascharoensuk; Bengt Fellström; Hallvard Holdaas; Vladimir Tesar; Andrzej Wiecek; Diederick Grobbee; Dick de Zeeuw; Carola Grönhagen-Riska; Tanaji Dasgupta; David Lewis; William Herrington; Marion Mafham; William Majoni; Karl Wallendszus; Richard Grimm; Terje Pedersen; Jonathan Tobert; Jane Armitage; Alex Baxter; Christopher Bray; Yiping Chen; Zhengming Chen; Michael Hill; Carol Knott; Sarah Parish; David Simpson; Peter Sleight; Alan Young; Rory Collins
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.